Drug profile · INN
fosnetupitant chloride hydrochloride
AKYNZEO
fosnetupitant chloride hydrochloride (AKYNZEO) is a neurokinin 1 receptor antagonist. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — fosnetupitant chloride hydrochloride
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
fosnetupitant chloride hydrochloride (AKYNZEO) is a neurokinin 1 receptor antagonist. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Neurokinin 1 receptor antagonist
Primary target: Substance-P receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is fosnetupitant chloride hydrochloride?
fosnetupitant chloride hydrochloride (AKYNZEO) is a neurokinin 1 receptor antagonist. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for fosnetupitant chloride hydrochloride?
AKYNZEO is a marketed brand name for fosnetupitant chloride hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of fosnetupitant chloride hydrochloride?
fosnetupitant chloride hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.